Venus Concept Secures FDA Clearance for Venus NOVA Platform Amid Financial Challenges.
ByAinvest
Tuesday, Nov 11, 2025 3:09 am ET1min read
VERO--
Venus Concept (VERO) has received FDA clearance for its Venus NOVA platform, a non-invasive treatment device for body, face, and skin. Despite innovative product developments, the company faces financial challenges, including negative profitability and high debt levels. Revenue growth has declined 32.5% over the past three years, and the company has a negative EPS of -50.78 and a net margin of -68.77%. The Altman Z-Score of -8.22 indicates a high risk of bankruptcy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet